Inhibition of the Sur1-Trpm4 Channel Reduces Neuroinflammation and Cognitive Impairment in Subarachnoid Hemorrhage

Cigdem Tosun, BS; David B. Kurland, BA; Rupal Mehta, MD; Rudy J. Castellani, MD; Joyce L. deJong, DO; Min Seong Kwon, PhD; Seung Kyoon Woo, PhD; Volodymyr Gerzanich, MD, PhD; J. Marc Simard, MD, PhD

Background and Purpose—Subarachnoid hemorrhage (SAH) can leave patients with memory impairments that may not recover fully. Molecular mechanisms are poorly understood, and no treatment is available. The sulfonylurea receptor 1–transient receptor potential melastatin 4 (Sur1-Trpm4) channel plays an important role in acute central nervous system injury. We evaluated upregulation of Sur1-Trpm4 in humans with SAH and, in rat models of SAH, we examined Sur1-Trpm4 upregulation, its role in barrier dysfunction and neuroinflammation, and its consequences on spatial learning.

Methods—We used Förster resonance energy transfer to detect coassociated Sur1 and Trpm4 in human autopsy brains with SAH. We studied rat models of SAH involving filament puncture of the internal carotid artery or injection of blood into the subarachnoid space of the entorhinal cortex. In rats, we used Förster resonance energy transfer and coimmunoprecipitation to detect coassociated Sur1 and Trpm4, we measured immunoglobulin G extravasation and tumor necrosis α overexpression as measures of barrier dysfunction and neuroinflammation, and we assessed spatial learning and memory on days 7 to 19.

Results—Sur1-Trpm4 channels were upregulated in humans and rats with SAH. In rats, inhibiting Sur1 using antisense or the selective Sur1 inhibitor glibenclamide reduced SAH-induced immunoglobulin G extravasation and tumor necrosis α overexpression. In models with entorhinal SAH, rats treated with glibenclamide for 7 days after SAH exhibited better platform search strategies and better performance on incremental and rapid spatial learning than vehicle-treated controls.

Conclusions—Sur1-Trpm4 channels are upregulated in humans and rats with SAH. Channel inhibition with glibenclamide may reduce neuroinflammation and the severity of cognitive deficits after SAH. (Stroke. 2013;44:3522-3528.)

Key Words: cognition ▪ memory ▪ subarachnoid hemorrhage ▪ sulfonylurea receptor ▪ transient receptor potential melastatin 4

Subarachnoid hemorrhage (SAH) can be devastating. Acutely, 30% of patients die, and those who survive may have poor prognoses. Among the worst cases are those in which the hemorrhage involves eloquent cortex, a situation frequently encountered with rupture of middle cerebral artery aneurysms.

SAH is associated with 2 neurological problems long considered to be intractable: cerebral vasospasm and cognitive impairment. Great progress has been made in characterizing molecular mechanisms of vasospasm, with recent clinical trials on endothelin antagonists showing that angiographic vasospasm can be prevented. By contrast, cognitive impairments including disorders of memory, executive function, and language, although well documented, are poorly understood molecularly, and no treatment is available.

The adenosine triphosphate (ATP)–binding cassette (ABC) transporters comprise a large superfamily of membrane proteins. Two members, Sur1 and Sur2, coassociate with heterologous pore-forming subunits to form ion channels. For Sur1, the most widely recognized association is with the ATP-sensitive K+ channel, Kir6.2, with which it forms K_ATP (Sur1-Kir6.2) channels in pancreatic β cells and neurons. Sur1 also associates with an ATP- and Ca2+-sensitive nonselective ion-channel, recently identified as transient receptor potential melastatin 4 (Trpm4), to form Sur1-Trpm4 channels (previously named Sur1-NCaATP channels). Both K_ATP (Sur1-Kir6.2) and Sur1-Trpm4 channels are regulated by Sur1, but the 2 have opposite functional effects: opening of K_ATP channels hyperpolarizes the cell, whereas opening of Sur1-Trpm4 channels depolarizes the cell. Unchecked opening of Sur1-Trpm4 channels may reduce neuroinflammation and cognitive impairment.

Received July 19, 2013; accepted September 10, 2013.

From the Departments of Neurosurgery (C.T., D.B.K., M.S.K., S.K.W., V.G., J.M.S.), Pathology (R.M., R.J.C., J.M.S.), and Physiology (J.M.S.), University of Maryland School of Medicine, Baltimore; and Department of Pathology, Western Michigan University School of Medicine, Kalamazoo, MI (J.L.d.J.).

The online-only Data Supplement is available with this article at http://stroke.ahajournals.org/lookup/suppl/doi:10.1161/STROKEAHA.113.002904/-/DC1.

Correspondence to J. Marc Simard, MD, PhD, Department of Neurosurgery, 22 S. Greene St, Suite S12D, Baltimore, MD 21201–1595. E-mail msimard@smail.umaryland.edu

© 2013 American Heart Association, Inc.

Stroke is available at http://stroke.ahajournals.org

DOI: 10.1161/STROKEAHA.113.002904
channels is associated with excess influx of Na⁺, which is accompanied by influx of Cl⁻ and H₂O, resulting in onotic cell swelling (cytotoxic edema) and, if severe, necrotic cell death. Involvement of microvascular endothelium results in the formation of ionic and vasogenic edema. Sur1 has been implicated in a rat model of SAH, with Sur1 blockade by glibenclamide associated with a significant reduction in several markers of neuroinflammation. However, demonstrating the involvement of Sur1 leaves unanswered the question of whether Kᵦᵦ (Sur1-Kir6.2) or Sur1-Trpm4 channels are involved. Recently, an antibody-based method using Förster resonance energy transfer (FRET) was developed that permits the identification of native coassociated Sur1 and Trpm4, signaling the presence of functional Sur1-Trpm4 channels, which can be used to detect the coassociation of 2 fluorescent-labeled proteins, occurs when the energy of an excited fluorophore, called the donor, is nonradiatively passed on to an acceptor fluorophore that is in close proximity. Recently, we used FRET to demonstrate Sur1-Trpm4 channels in rat tissues after spinal cord injury. Here, we show that coassociated Sur1 and Trpm4 can be identified in cortical tissues from patients with SAH, as well as in cortical tissues from a rat model of SAH. In addition, we show that the channel plays a crucial role in blood–brain barrier (BBB) permeability and in neuroinflammation, and we show that in rat models of SAH involving eloquent cortex, blockade of the channel by the selective Sur1 inhibitor, glibenclamide, significantly ameliorates impairments in spatial learning and memory.

Methods

Human Tissues
Tissue collection protocols were approved by the Institutional Review Boards of the University of Maryland, Baltimore, MD, and the Sparrow Hospital, Lansing, MI. The cases of 7 patients dying within several days of acute SAH who underwent autopsy were identified retrospectively. Demographic and other information on these patients is given in Table 1 in the online-only Data Supplement. Gross and histological validation of the presence of acute SAH was made in all cases by a neuropathologist. Cortex involved in SAH was analyzed. As negative controls, frontal and parietal cortices from 5 normal autopsy brains with documented absence of SAH, ipsilateral ischemia, or other central nervous system pathology also were examined. Demographic and other information on these patients is given in Table 1 in the online-only Data Supplement. As positive controls for Kᵦᵦ (Sur1-Kir6.2), normal pancreases and hippocampi obtained at autopsy also were evaluated.

Rat Model of SAH
Animal experiments were performed under a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Maryland. All experiments were performed in accordance with the relevant guidelines and regulations in the United States National Institutes of Health Guide for the Care and Use of Laboratory Animals. All efforts were made to minimize the number of animals used and their suffering. Male Wistar rats (300–350 g, Harlan, Indianapolis, IN) were anesthetized (ketamine 60 mg/kg and xylazine 7.5 mg/kg intraperitoneally). SpO2 via pulse oximetry and temperature were carefully regulated, and all surgical procedures were performed aseptically. SAH was produced either by (1) stereotactic injection of fresh nonheparinized autologous tail blood into the subarachnoid space of the entorhinal cortex, except that 150 μL of blood was injected >20 minutes, either unilaterally or bilaterally; or (2) by filament puncture of the internal carotid artery. Three series of rats with blood injections into the entorhinal cortex were studied. In series 1, 11 rats underwent entorhinal SAH and were euthanized 24 to 48 hours later for immunohistochemistry, FRET, or coimmunoprecipitation experiments. In series 2, 14 rats underwent unilateral entorhinal SAH and in series 3, 18 rats underwent bilateral entorhinal SAH; for series 2 and 3, half in each series were randomly assigned to vehicle or glibenclamide treatment. On days 7 to 19 after SAH, all were evaluated in the Morris water maze (MWM) by blinded investigators, after which they were euthanized. No rat in series 2 or 3 was excluded. Series 4 consisted of 7 uninjured rats that served as controls for the MWM testing. For Series 5, 6 rats underwent filament puncture of the internal carotid artery and were administered antisense oligodeoxynucleotide (AS-ODN) directed against Abcc8 or scrambled oligodeoxynucleotide (Scr-ODN; 3 rats per group). The brains of these rats were analyzed at 24 hours for immunoglobulin G extravasation and tumor necrosis α (TNFα) expression.

Glibenclamide Treatment
Drug formulation of glibenclamide (#G2539; Sigma, St. Louis, MO) in dimethyl sulfoxide and the preparation of miniosmotic pumps were as described. Treatment consisted of (1) administering a single loading dose of glibenclamide (10 μg/kg) or an equivalent volume of vehicle IP within 10 minutes of completing the injection(s) of blood; (2) continuous infusion via miniosmotic pump (Alzet 2001, 1.0 μL/hr; Alzet Corp, Cupertino, CA) beginning at the end of surgery, resulting in delivery of 200 μg/hr or an equivalent volume of vehicle subcutaneously for 1 week. The dose of glibenclamide used here has been shown to not result in hypoglycemia.

Antisense Treatment
AS-ODN directed against Abcc8 and Scr-ODN were prepared and administered IV via miniosmotic pump as described, starting within 10 minutes of SAH and continuing for 24 hours.

Histochemistry and FRET
Immunohistochemistry and antibody-based FRET were performed using custom anti-Sur1 and anti-Trpm4 antibodies, as described, except that FRET imaging and measurements of FRET efficiency were performed using a Zeiss LSM710 confocal microscope. Semiquantitative analysis of immunolabeling for Sur1, which was used as a proxy for Sur1-Trpm4 channels, was performed as described. Quantitative analyses of immunoglobulin G (1:200; Santa Cruz Biotechnology) and TNFα (1:100; Santa Cruz Biotechnology) immunolabeling in cortex adjacent to SAH, Black Gold II (Millipore, Temecula, CA) labeling of perforant pathway, Fluoro-Jade C staining (Histo-Chem, Jefferson, AR) of hippocampus, and 4',6-diamidino-2-phenylindole (DAPI; Invitrogen, Eugene, OR) labeling of pyknotic nuclei in the dentate gyrus were performed as described.

Coimmunoprecipitation
Coimmunoprecipitation and immunoblot were performed using custom anti-Sur1 and anti-Trpm4 antibodies, as described.

Morris Water Maze
MWM learning took place on days 7 to 11 after SAH using the device and the paradigms described. The memory probe was performed on day 12, and rapid learning was tested on day 19 after SAH. Platform search strategies were analyzed according to Brody and Holtzman. Investigators evaluating MWM performance were blinded to treatment group.

Data Analysis
Data are presented as means±SE. Statistical analyses were performed using Origin Pro (V8; OriginLab Corp, North Hampton MA). Student
Sur1-Trpm4 in Humans With SAH

We first validated the method of FRET using COS-7 cells heterologously expressing Sur1 and Trpm4 (Figure I in the online-only Data Supplement) and human and rat pancreas, which expresses KATP channels, that is, coassociated Sur1 and Kir6.2 (Figure II in the online-only Data Supplement). In all cases, Sur1 was found by FRET to coassociate with the pore-forming subunit, either Kir6.2 or Trpm4, whereas appropriate controls did not show FRET.

We studied cortical tissues of patients who were verified at autopsy to have SAH from a ruptured saccular aneurysm or another cause (Table I in the online-only Data Supplement). Cortex adjacent to SAH showed prominent upregulation of Sur1 (Figure 1A and 1B) compared with control cortex (Figure III in the online-only Data Supplement). Similarly, cortex adjacent to SAH showed prominent upregulation of Trpm4 (Figure 1B) compared with control cortex (Figure III in the online-only Data Supplement). Sur1 and Trpm4 upregulation colocalized to both microvessels and neurons, with FRET analysis demonstrating that the 2 proteins coassociated (Figure 1C). FRET efficiency, which reflects the proximity of the 2 fluorophores, was ≈11% to 14% in positive controls (COS-7 expression system and human pancreas), 0% in a negative control, and ≈10% in cortical structures from patients with SAH (Figure 1C). Semiquantitative analysis showed that the abundance of Sur1-Trpm4 channels in microvessels, neurons, and astrocytes varied between cases of SAH, but always exceeded findings in control brains (Table I in the online-only Data Supplement). Sur1 expression is not influenced by postmortem interval.17

Sur1-Trpm4 in Rats With SAH

Brain tissues from the entorhinal SAH model were studied 24 to 48 hours after SAH. Cortical microvessels, neurons, and astrocytes near the SAH showed expression of both Sur1 and Trpm4, and FRET confirmed that Sur1 and Trpm4 were coassociated (Figure 2A–C). Cortex adjacent to SAH that expressed Sur1 in microvessels and cells exhibited minimal expression of Kir6.2 and no FRET, consistent with absence of KATP (Figure II in the online-only Data Supplement). Control brains showed little or no immunolabeling for Sur1 or Trpm4 and no FRET (not shown).13

The coassociation of Sur1 and Trpm4 demonstrated by FRET was verified by coimmunoprecipitation. Normally, Trpm4 is expressed predominantly in restricted areas of rat brain,21 but minimally in cortex (Figure III in the online-only Data Supplement). Compared with uninjured control tissues, there was a 3-fold increase in Trpm4 in tissues adjacent to SAH (Figure 2D). Coimmunoprecipitation using anti-Sur1 antibody for immunolocalization revealed an 8-fold increase in coassociated Sur1-Trpm4 (Figure 2D).

Inhibition of Sur1

To assess the downstream consequence of Sur1-Trpm4 channel upregulation, we evaluated the effect of Abce8 gene suppression on SAH-induced BBB permeability. A pathological increase in BBB permeability was identified in 2 models of SAH, one with blood injection into the entorhinal cortex, and the other with filament puncture of the internal carotid artery (Figure 3), demonstrating that BBB dysfunction in cortex adjacent to SAH is model independent. AS-ODN directed against Abce8 significantly reduced Sur1 expression in cortex adjacent to SAH (Figure 3A), and significantly reduced the SAH-induced abnormality in barrier permeability (Figure 3B).

Pharmacological inhibition of Sur1 with glibenclamide was as effective as gene suppression of Abce8 in ameliorating barrier dysfunction (Figure 3C). Extravasation of serum proteins promotes neuroinflammation.22 We evaluated the impact of Sur1 inhibition on SAH-induced overexpression of the acute phase reactant cytokine, TNFα. Both gene suppression of Abce8 with antisense and pharmacological inhibition of Sur1 with glibenclamide
reduced TNFα expression in adjacent cortical tissues ≈4-fold (Figure 4), confirming the critical proinflammatory role of Sur1 in SAH.13

Spatial Learning and Memory
We used the MWM to assess incremental and rapid spatial learning and memory in rats with either unilateral or bilateral entorhinal SAH that had been administered either glibenclamide or vehicle after SAH.

Rats with unilateral entorhinal SAH performed well overall. Except for the first day of training (day 7 after SAH), when they took longer and used less efficient platform search strategies, their performance during incremental learning was similar to uninjured naïve control rats (Figure IV in the online-only Data Supplement). Similarly, there was no deficit in the memory probe on day 12 (Figure IV in the online-only Data Supplement). However, rats with unilateral entorhinal SAH treated with vehicle exhibited a significant deficit in rapid spatial learning on day 19 that was largely absent in rats with unilateral entorhinal SAH treated with glibenclamide (Figure IV in the online-only Data Supplement).

Rats with bilateral entorhinal SAH that were administered vehicle performed poorly. They repeatedly took longer to find the platform and used inefficient search strategies, compared with uninjured naïve control rats (Figure 5A and 5B). Both the memory probe on day 12 and the test of rapid learning on day 19 showed that they swam in the correct quadrant no more than a quarter of the time, as expected from chance alone (Figure 5C and 5D). By comparison, rats with bilateral entorhinal SAH administered glibenclamide performed better, with incremental learning on days 7 to 11, platform search strategy on day 11, and memory probe on day 12 being indistinguishable from uninjured naïve control rats (Figure 5A–C). Only in the test of rapid learning on day 19 did glibenclamide-treated rats with bilateral entorhinal SAH exhibit a significant deficit, with their performance not significantly better than vehicle-treated rats (Figure 5D).

Tissue Preservation
Rapid spatial learning is a hippocampus-specific task. We examined the hippocampi, which are physically remote from the entorhinal SAH, but which receive important afferent synaptic input from the entorhinal cortex.23 Quantitative analyses were performed for Black Gold II labeling of perforant pathway white matter, Fluoro-Jade C staining of hippocampus, and DAPI staining of pyknotic nuclei in the dentate gyrus. As previously reported for this model,14 these measures of hippocampal injury were present in vehicle controls (Figure 6). Glibenclamide treatment significantly reduced each measure of injury (Figure 6).

Discussion
The major finding of this study is that, in the brains of humans and rats after SAH, but not in controls, coassociated Sur1 and Trpm4 subunits were readily detected, either by FRET or by coimmunoprecipitation, consistent with de novo upregulation of Sur1-Trpm4 channels.9 In the human cases, available tissues were formalin fixed, precluding coimmunoprecipitation, and so the coassociation of Sur1 and Trpm4 was demonstrated using FRET. In rats, where unfixed tissues were available, coassociation was demonstrated using both FRET and coimmunoprecipitation. Sur1-Trpm4 channels were identified in microvascular endothelium, neurons, and astrocytes. Our previous report identified de novo upregulation of Sur1 in a model of SAH,11 but that study left unanswered the question of whether Sur1 was associated with Kir6.2 (K<sub>ATP</sub>), or with Trpm4. The present study provides strong evidence that Sur1-Trpm4, not K<sub>ATP</sub> channels are upregulated in cortex adjacent to SAH.

The present study implicates the Sur1-Trpm4 channel in SAH-induced abnormal BBB permeability and neuroinflammation, with blockade of the channel resulting in significant
reductions in extravasated serum proteins, TNFα overexpression, and deficits in spatial learning and memory. Vasogenic edema attributable to breakdown of the BBB is widely recognized for its role in brain swelling, but the associated extravasation of serum proteins is underappreciated as a potent cause of neuroinflammation resulting in neuronal dysfunction.22 Available treatments for edema such as osmotherapy may reduce swelling but are unlikely to alter the proinflammatory effects of extravasated proteins. Preventing vasogenic edema by maintaining the integrity of the BBB is preferable to osmotherapy for treating the already swollen brain.

Compared with other pathological effects of SAH, especially vasospasm, there has been a paucity of attention focused on mechanisms of cognitive impairment in animal models of SAH. In the endovascular perforation model, which causes transient global ischemia and ≈33% mortality, neurobehavioral consequences are generally unimpressive, with surviving animals having only mild or no abnormalities in MWM testing.24 Models with injection of 250 to 300 μL of blood into the prechiasmatic cistern yield modest abnormalities in MWM testing on days 4 to 5 after SAH25,26; however, to our knowledge, there are no reports of deficits persisting >5 days.

We studied a model designed to affect what is arguably the most eloquent cortex in the rat. The neuronal circuitry involving entorhinal cortices, perforant pathway, and dentate gyrus granule cells plays a critical role in spatial learning,23 which is readily evaluated in rats using MWM paradigms. We previously showed that SAH (50 μL injection) involving the entorhinal cortex results in demyelination of the perforant pathway and transynaptic apoptosis of dentate gyrus granule cells, and is associated with neuroinflammation that extended along this pathway into the hippocampus.14 As predicted by the known function of this neuronal circuitry,23 here we found that unilateral entorhinal SAH resulted in mild deficits in all spatial learning tasks except rapid spatial learning on day 19, whereas bilateral entorhinal SAH was marked by major deficits in all spatial learning tasks assessed during days 7 to 19 after SAH. Abnormalities in spatial learning and memory in these models were ameliorated by glibenclamide, in concert with better

**Figure 3.** Antisense against Abcc8 and glibenclamide reduce immunoglobulin G (IgG) extravasation at 24 hours. A and B, Cortex adjacent to subarachnoid hemorrhage (SAH) immunolabeled for Sur1 (A) or IgG (B) from rats administered Scr-ODN or AS-ODN; box plots of quantitative analyses are shown; *, P<0.05; **, P<0.01; 3 rats per group; filament puncture model. C, Cortex adjacent to SAH immunolabeled for IgG from rats administered vehicle (Veh) or glibenclamide (Glib); box plots of quantitative analyses are shown; **, P<0.01; 8 rats per group; entorhinal cortex injection model.

**Figure 4.** Antisense against Abcc8 and glibenclamide reduce tumor necrosis α (TNFα) overexpression at 24 hours. A, Cortex adjacent to subarachnoid hemorrhage (SAH) immunolabeled for TNFα from rats administered Scr-ODN or AS-ODN; box plots of quantitative analyses are shown; **, P<0.01; same rats as in Figure 3A and 3B. B, Cortex adjacent to SAH immunolabeled for immunoglobulin G (IgG) from rats administered vehicle (Veh) or glibenclamide (Glib); box plots of quantitative analyses are shown; **, P<0.01; the same rats as in Figure 3C.
Conclusions

We conclude that Sur1-Trpm4 channels are upregulated in humans and rats with SAH, and that channel inhibition with glibenclamide may be useful for reducing neuroinflammation and cognitive deficits after SAH.

Disclosures

Dr Simard holds a US patent (7,285,574), a novel nonselective cation-channel in neural cells and methods for treating brain swelling. Dr Simard is a member of the scientific advisory board and holds shares in Remedy Pharmaceuticals. No support, direct or indirect, was provided to Dr Simard, or for this project by Remedy Pharmaceuticals. The other authors report no conflicts.

References

Inhibition of the Sur1-Trpm4 Channel Reduces Neuroinflammation and Cognitive Impairment in Subarachnoid Hemorrhage

Cigdem Tosun, David B. Kurland, Rupal Mehta, Rudy J. Castellani, Joyce L. de Jong, Min Seong Kwon, Seung Kyoong Woo, Volodymyr Gerzanich and J. Marc Simard

*Stroke*. 2013;44:3522-3528; originally published online October 10, 2013; doi: 10.1161/STROKEAHA.113.002904

*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/44/12/3522

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2013/10/10/STROKEAHA.113.002904.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org/subscriptions/
SUPPLEMENTAL MATERIAL

Inhibition of the Sur1-Trpm4 channel reduces neuroinflammation and cognitive impairment in subarachnoid hemorrhage

Supplementary Table I. Demographics of patients with and without SAH.

<table>
<thead>
<tr>
<th>Case #</th>
<th>Age (y)</th>
<th>Sex</th>
<th>Cause of Acute SAH</th>
<th>Cause of death</th>
<th>Sur1 abundance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>vessels</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>neurons</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>astrocytes</td>
</tr>
<tr>
<td><strong>Subarachnoid hemorrhage</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>40 F</td>
<td>MCA aneurysm</td>
<td>acute SAH</td>
<td>++++</td>
<td>++++</td>
</tr>
<tr>
<td>2</td>
<td>55 M</td>
<td>Acom aneurysm</td>
<td>acute SAH</td>
<td>++++</td>
<td>++</td>
</tr>
<tr>
<td>3</td>
<td>46 M</td>
<td>MCA aneurysm</td>
<td>acute SAH</td>
<td>++</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>72 F</td>
<td>PICA aneurysm</td>
<td>acute SAH</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td>5</td>
<td>44 M</td>
<td>AVM-associated aneurysm</td>
<td>acute SAH</td>
<td>+++</td>
<td>+</td>
</tr>
<tr>
<td>6</td>
<td>56 F</td>
<td>suspected fall</td>
<td>acute pneumonia/ARDS</td>
<td>++++</td>
<td>+++</td>
</tr>
<tr>
<td>7</td>
<td>56 F</td>
<td>venous infarct, thalamus</td>
<td>H1N1 Flu/ARDS</td>
<td>+++</td>
<td>++</td>
</tr>
<tr>
<td><strong>Control normal brain</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>34 M</td>
<td>pneumothorax/pneumonia</td>
<td></td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>58 M</td>
<td>status asthmaticus</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>52 M</td>
<td>acute bronchopneumonia</td>
<td></td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>4</td>
<td>57 F</td>
<td>acute rupture of aortic aneurysm</td>
<td></td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>33 F</td>
<td>acute bronchopneumonia</td>
<td></td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations: Acom, anterior communicating artery; ARDS, acute respiratory distress syndrome; AVM, arteriovenous malformation; CMML, chronic myelomonocytic leukemia; F, female; M, male; MCA, middle cerebral artery; PICA, posterior inferior cerebellar artery; SAH, subarachnoid hemorrhage; y, years.
Supplementary Figure I. Validation of antibodies for antibody-based FRET analysis. A–C: COS-7 cells expressing either Sur1 or Trpm4 (A) or co-expressing both (B,C) were incubated with either anti-Sur1 or anti-Trpm4 antibodies (B) or both (A,C) followed by anti-rabbit Cy3-conjugated plus anti-goat Cy5-conjugated secondary antibodies (A–C). Fluorescence images of the 2 fluorophores (left and middle columns), as well as FRET images (right column) are shown; methods as in Woo et al.1; representative of 6 replicates; note that the primary antibodies against Sur1 and Trpm4 do not cross-react.
Supplementary Figure II. FRET analysis of Sur1-Kir6.2 in native tissues. A,B: Human (A) and rat (B) pancreas immunolabeled for Sur1 and Kir6.2, with FRET showing that Sur1 and Kir6.2 co-associate to form KATP channels.² C: Rat cortex adjacent to SAH immunolabeled for Sur1 and Kir6.2, showing minimal Kir6.2, and FRET showing that Sur1 and Kir6.2 do not co-associate in cortex adjacent to SAH; representative of 5 replicates.

Supplementary Figure III. Normal human cortex expresses minimal Sur1 and Trpm4. A: Normal human cortex immunolabeled for Sur1 shows minimal expression of Sur1;³ normal human hippocampus is shown as a positive control;⁴ nuclei stained with DAPI. B: Normal human cortex immunolabeled for Trpm4 shows minimal expression of Trpm4; normal human colon is shown as a positive control.⁶
Supplementary Figure IV. Glibenclamide reduces impairment in rapid spatial learning in rats with unilateral entorhinal SAH. A,B: Time spent searching for the submerged platform (A) and the percent time spent in 1 of 3 platform search strategies (B) during incremental learning in uninjured naïve controls (7 rats), and in rats with unilateral entorhinal SAH administered vehicle (7 rats) or glibenclamide (7 rats). C,D: Time spent in the correct quadrant during the memory probe (C) and during the test of rapid learning (D) in the same rats. *, $P<0.05$ comparing naïve and vehicle treatment; there was no statistical difference comparing naïve and glibenclamide treatment.
Supplementary References


